Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
C E Geyer, J E Garber, R D Gelber, G Yothers, M Taboada, L Ross, P Rastogi, K Cui, A Arahmani, G Aktan, A C Armstrong, M Arnedos, J Balmaña, J Bergh, J Bliss, S Delaloge, S M Domchek, A Eisen, F Elsafy, L E Fein, A Fielding, J M Ford, S Friedman, K A Gelmon, L Gianni, M Gnant, S J Hollingsworth, S-A Im, A Jager, Ó Þ Jóhannsson, S R Lakhani, W Janni, B Linderholm, T-W Liu, N Loman, L Korde, S Loibl, P C Lucas, F Marmé, E Martinez de Dueñas, R McConnell, K-A Phillips, M Piccart, G Rossi, R Schmutzler, E Senkus, Z Shao, P Sharma, C F Singer, T Španić, E Stickeler, M Toi, T A Traina, G Viale, G Zoppoli, Y H Park, R Yerushalmi, H Yang, D Pang, K H Jung, A Mailliez, Z Fan, I Tennevet, J Zhang, T Nagy, G S Sonke, Q Sun, M Parton, M A Colleoni, M Schmidt, A M Brufsky, W Razaq, B Kaufman, D Cameron, C Campbell, A N J Tutt
Annals of oncology : official journal of the European Society for Medical Oncology 2022;33(12):1250-1268